Mobic Generic Competition Possible In Early 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer Ingelheim brand rings up $293 mil. in first quarter sales as biggest beneficiary from COX-2 safety issues. Mobic loses exclusivity April 13, although generics are unlikely to enter the market for at least nine months.
You may also be interested in...
"Best Buy" NSAID Rxs Up Since Vioxx Withdrawal, But Mobic Growing Faster, Consumers Union Says
Prescriptions for Abbott/Boehringer Ingelheim's Mobic doubled from September to March and the average retail price rose 9% in the same period, Consumers Union notes. Scripts for ibuprofen were up 28%, but prices were "relatively flat," the report says.
"Best Buy" NSAID Rxs Up Since Vioxx Withdrawal, But Mobic Growing Faster, Consumers Union Says
Prescriptions for Abbott/Boehringer Ingelheim's Mobic doubled from September to March and the average retail price rose 9% in the same period, Consumers Union notes. Scripts for ibuprofen were up 28%, but prices were "relatively flat," the report says.
FDA's COX-2 Safety Plan: Remove Bextra, Add "Black Box" To Celebrex
Pfizer has not yet agreed to withdraw Bextra but will suspend marketing pending further discussions with FDA. Boxed warning on all prescription NSAIDS – including Celebrex – will discuss increased cardiovascular and gastrointestinal risk. FDA's decision comes two days after Pfizer tells analysts COX-2 inhibitor sales are stabilizing.